Rates of regional tau accumulation in ageing and across the

Alzheimer's disease continuum: An AIBL ¹⁸F-MK6240 PET study

Natasha Krishnadas^{1,2}, Vincent Doré^{2,3}, Jo Robertson⁴, Larry Ward⁴, Christopher Fowler⁴, Colin L Masters⁴, Pierrick Bourgeat⁵, Jurgen Fripp⁵, Victor L Villemagne⁶, Christopher C Rowe^{1,2,4}

¹ Florey Department of Neurosciences & Mental Health, The University of Melbourne,

Parkville, VIC 3052, Australia

² Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC 3084, Australia

³ Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne,

Victoria, Australia

⁴ Florey Institute of Neurosciences & Mental Health, Parkville, VIC 3010, Australia

⁵ Health and Biosecurity Flagship, The Australian eHealth Research Centre, Brisbane,

QLD, Australia

⁶ Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA

Running title: Longitudinal tau ¹⁸F-MK6240

Corresponding author:

Christopher C. Rowe

Department of Molecular Imaging & Therapy

Austin Health

Level 1 Harold Stokes Building

145 Studley Road, Heidelberg

VIC 3084, Australia

Telephone: 61 3 94965183; Fax: 61 3 94965663

Email: Christopher.ROWE@austin.org.au

Abstract

Background

Tau PET imaging enables prospective longitudinal observation of the rate and location of tau accumulation in Alzheimer's disease (AD). ¹⁸F-MK6240 is a newer, high affinity tracer for the paired helical filaments of tau in AD. It is widely used in clinical trials, despite sparse longitudinal natural history data. We aimed to evaluate the impact of disease stage, and two reference regions on the magnitude and effect size of regional change.

Methods

One hundred and fifty-eight participants: 83 cognitively unimpaired (CU) A β -, 37 CU A β +, 19 mild cognitively impaired (MCI) A β + and 19 AD A β + had annual ¹⁸F-MK6240 PET for one or two years (mean 1.6 years). Standardized uptake value ratios (SUVR) were generated for three in-house composite ROI: mesial temporal (Me), temporoparietal (Te), and rest of neocortex (R), and a Free-Surfer derived meta-temporal (MT) ROI. Two reference regions were examined: cerebellar cortex (SUVR_{cb}) and eroded subcortical white matter (SUVR_{wM}).

Results

Low rates of accumulation were seen in CU A β -, predominantly in the mesial temporal lobe (MTL). In CU A β +, increase was greatest in the MTL, particularly the amygdala. In MCI A β +, a similar increase was seen in MTL, but also globally in the cortex. In AD A β +, greatest increase was in temporoparietal and frontal regions, with a decrease in the MTL. In CU and MCI increases were greater using SUVR_{WM}. In AD, the SUVR_{Cb} showed marginally greater increase. Interpolation of the data suggests it takes approximately two decades to accumulate tau to the typical levels found in AD, similar to the rates of accumulation of A β plaques.

Conclusions

The rate of tau accumulation varies according to brain region and baseline disease stage, confirming previous reports. The PET measured change is greater, with fewer outliers, using an eroded white matter reference region, except in AD. While the eroded subcortical white matter reference may be preferred for trials in preclinical AD, the cerebellar cortex would be preferred for trials in symptomatic AD.

Trial registration

Not applicable.

Key words: Tau, ¹⁸F-MK6240, Positron Emission Tomography (PET), Alzheimer's disease (AD), Longitudinal.

Background

Intracellular tau neurofibrillary tangles (NFT), along with extracellular amyloid- β (A β) plaques, are two pathological hallmarks of Alzheimer's disease (AD). In AD, the spatial distribution of brain tau aggregates is linked with cognitive impairment in a domain-specific manner (1-3). Tau is also closely linked with the development of neurodegeneration (3-7). Longitudinal *in vivo* tracking of tau can facilitate our understanding of the natural trajectory of tau, its interactivity with A β , and associations with the clinical features of AD. Serial tau PET has also been proposed as a surrogate marker for disease progression in AD clinical trials (8) and has been included as an outcome measure in trial sub-analyses aiming to evaluate the impact of anti-A β therapies on tau burden (9, 10).

Tau tracer ¹⁸F-MK6240 has high affinity and selectivity for tau NFT in AD (11, 12). Serial imaging with ¹⁸F-MK6240 has reported detectable rates of tau accumulation in both preclinical and symptomatic AD stages (13). Detection of tau accumulation in

preclinical AD is advantageous for clinical trials that are aiming to target this earlier stage of disease (14). The main aim of this study was to evaluate the rates of tau accumulation in ageing (CU A β -), preclinical AD (CU A β +), and symptomatic disease stages (A β + mild cognitive impairment [MCI] and Alzheimer's disease dementia [AD]) using ¹⁸F-MK6240. The second aim was to investigate the impact of two reference regions (cerebellar cortex and eroded subcortical white matter) on the magnitude and effect size of regional change.

Methods

Participants

Participants from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL) (15) and the Australian Dementia Network (ADNeT) who completed baseline and one or more follow-up tau ¹⁸F-MK6240 PET scans before July 2021 were included in this study if they met the following criteria: 1) \geq 50 years of age; 2) were fluent in English; 3) had completed at least 7 years of education; and 4) did not have any history of neurological or psychiatric disorders, drug or alcohol abuse or dependence, or any other unstable medical condition. All participants complete neuropsychology assessments every 12 to 18 months, as previously described (15). Based on available clinical information and neuropsychology assessments, a multi-disciplinary clinical review panel, blind to A β and tau PET results, determines each participant's clinical classification. Participants were deemed to be cognitively unimpaired (CU) if their performance on neuropsychology assessments was within 1.5 standard deviations of published normative data for their age group. A diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease dementia (AD) was assigned in accordance with international consensus criteria, as previously described (16). This

study has been approved by the institutional review boards of all participating institutions, and all participants signed an informed consent form.

Image acquisition

Tau PET imaging involved the intravenous administration of 185MBq ($\pm 10\%$) of ¹⁸F-MK6240 with a 20-minute acquisition commencing 90-minutes post-injection. A β PET imaging involved the intravenous administration of 200MBq ($\pm 10\%$) of ¹⁸F-NAV4694 with a 20-minute acquisition time commencing 50-minutes post-injection. PET scans were acquired on either a Philips TF64 PET/CT or a Siemens Biograph mCT. PET scans for each participant were performed on the same scanner at baseline and follow-up. Low dose CT was obtained for attenuation correction.

Image analysis

Tau ¹⁸F-MK6240 PET scans were spatially normalized using the MR-less CapAIBL PCA-based approach (17) and scaled using two reference regions: 1) cerebellar cortex; and 2) eroded subcortical white matter. A gray matter inclusion mask and a meninges exclusion mask were applied. ¹⁸F-MK6240 standardized uptake value ratio (SUVR) was estimated for three in-house composite ROI: i) mesial temporal, Me (comprising entorhinal cortex, amygdala, hippocampus, and parahippocampus); ii) temporoparietal, Te (comprising inferior and middle temporal, fusiform, supramarginal and angular gyri, posterior cingulate/ precuneus, superior and inferior parietal, and lateral occipital cortex); and iii) rest of neocortex, R (comprising dorsolateral and ventrolateral prefrontal, orbitofrontal cortex, gyrus rectus, superior temporal and anterior cingulate), as previously described (18). Tau ¹⁸F-MK6240 SUVR was also estimated in a metatemporal composite, MT (comprising Free-Surfer derived entorhinal cortex, parahippocampus, amygdala, inferior temporal, fusiform, and middle temporal cortex, ROI) (19).

A β PET scans were spatially normalized using the MR-less CapAIBL approach (https://milxcloud.csiro.au/tools/capaibl), and the CapAIBL calibrated Centiloid method was applied for quantification (20). A Centiloid value of 25 was used to discriminate high (A β +) and low (A β -) A β scans.

Vertex-based surface analysis

All ¹⁸F-MK6240 scans were in the same standard space and were projected onto the cortical surface using CapAIBL. Vertex-based surface analysis was used to estimate the mean annual rate of tau accumulation (change in SUVR/ year) for each of the clinical groups, scaled using two reference regions: 1) cerebellar cortex; and 2) eroded subcortical white matter.

Statistical method

Demographic data were analyzed using an independent samples t-test for continuous data, and Chi-square test of independence for categorical data, with a threshold of significance of p<0.05. Effect size was reported as Cohen's *d*. Annual change in ¹⁸F-MK6240 SUVR in each composite ROI was estimated as the slope obtained from linear regression of SUVR (independent variable) by Δ time (dependent variable). Annual percentage change in ¹⁸F-MK6240 SUVR in each composite was estimated as follows:



Results

Participants

The cohort comprised 158 participants: 83 CU A β -, 37 CU A β +, 38 cognitively impaired A β + (19 with MCI and 19 with AD dementia). Table 1 shows the demographic characteristics of the cohort at baseline.

Table 1 Cohort demographic characteristics at baseline

	CU Aβ-	CU Aβ+	MCI A β +	AD $A\beta +$
	<i>n</i> = 83	<i>n</i> = 37	<i>n</i> = 19	<i>n</i> = 19
Age (yrs)	74.6±4.4	78.2±6.2**	77.5±7.2	69.7±8.5*
Sex, F (%)	48.2%	56.8%	47.4%	42.1%
APOE $\varepsilon 4 + (\%)^{a}$	26.5%	63.9%**	52.9%*	57.1%*
Centiloid	4.5±9.1	80.1±38.5**	99.9±51.3**	117.7±38.0**
Baseline MMSE	28.6±1.2	27.9±1.5*	26.3±1.7**	22.2±3.5**
Duration of follow-up (yrs)	1.68 (0.47)	1.73 (0.53)	1.61 (0.49)	1.50 (0.45)

T-test (one-tailed) * p<0.05, ** p<0.001 compared to $\overline{\text{CU A\beta}}$ -.

^a APOE genotype only available for 149/158 participants.

Tau accumulation using vertex-based surface analysis

Vertex-based surface analysis was performed to demonstrate the spatial distribution and rate of ¹⁸F-MK6240 accumulation (SUVR/ year) across the clinical groups, normalized to the cerebellar cortex (Figure 1). Analysis in CU A β - individuals detected minimal tau accumulation. CU A β + individuals showed tau accumulation in the mesial temporal cortex, inferior and lateral temporal gyri, and clusters in the precuneus and angular gyri. MCI A β + individuals were observed to have tau accumulation in the precuneus,

superior and lateral temporal, occipital, parietal, and prefrontal cortices. AD $A\beta$ + individuals were observed to have tau accumulation in the precuneus, temporal, parietal, occipital, and prefrontal cortices, with no accumulation in the mesial temporal cortex. The analysis was also performed using SUVR_{WM} (Supplementary Figure 1). With this reference region, CU $A\beta$ - individuals were observed to have low rates of tau accumulation in the mesial temporal and temporal cortices. The spatial distribution of tau observed in the CU $A\beta$ +, MCI $A\beta$ + and AD $A\beta$ + groups was similar, irrespective of the reference region. However, higher rates of tau accumulation were observed in the CU $A\beta$ + and MCI $A\beta$ + groups, and lower rates of tau accumulation were observed in the AD $A\beta$ + groups for SUVR_{WM} than SUVR_{Cb} (Figure 1, Supplementary Figure 1).

Tau accumulation in composite brain regions of interest

Baseline SUVR, annual tau SUVR change, and annual tau SUVR percentage change were estimated in each composite ROI for the clinical groups. Results are shown for two reference regions: a) cerebellar cortex (Table 2, Figure 2A, and Figure 3A); and b) eroded subcortical white matter (Table 3, Figure 2B, and Figure 3B). Tau accumulation across individual brain regions for each of the clinical groups is shown in Figure 4. Scans normalized to the cerebellar cortex reference region showed that CU Aβindividuals had low levels of tau accumulation in Me (1.1%/ year) and MT (1.3%/ year), and no tau accumulation in Te and R (<1%/ year) (Supplementary Table 1). CU A β + individuals showed tau accumulation in Me (2.8%/ year), MT (3.2%/ year), and Te (2.3%/ year), and very low rates of accumulation in R (0.6%/year) (Supplementary Table 1). MCI A β + individuals showed the highest rates of tau accumulation in MT (1.6%/year) and Te (2.3%/year), with lower rates in Me (0.9%/year) and R (1.3%/year). AD A β + individuals showed the highest rates of tau accumulation in Te (2.3%) and R (3.8%), with a negative rate of change in Me (-1.4%/yr) and lower rate of change in MT (0.6%/year respectively) (Supplementary Table 1).

Scans normalized to the eroded subcortical white matter reference region showed that CU A β - individuals had low levels of tau accumulation in Me (1.8%/ year), MT (2%/year), but also Te (1.5%/year) (Supplementary Table 2). CU A β + individuals showed tau accumulation in Me (3.2%/ year), MT (3.6%/year), and Te (2.7%/ year), with low rates of accumulation in R (0.97%/year) (Supplementary Table 2). MCI A β + individuals showed tau accumulation in Me (2.4%/ year), and across the cortex (3.1%/year in MT, 3.7%/ year in Te, and 2.7%/year in R) (Supplementary Table 2). AD A β + individuals showed tau accumulation in Te (1.1%/year) and R (2.7%/year), with a negative rate of change in Me (-2.5%/year) and MT (-0.5%/year) (Supplementary Table 2). Higher annual percentage change estimates were observed using the subcortical white matter reference region for the CU A β -, CU A β + and MCI A β + groups, while higher estimates were observed using the cerebellar cortex reference region for the AD A β + group.

The effect size for annual percentage change in tau SUVR for the CU A β + group compared to the CU A β - group was similar using the SUVR_{Cb} and SUVR_{WM} (Me, d = 0.30 vs 0.24; MT, d = 0.36 vs 0.31; Te, d = 0.30 vs 0.23; R, d = 0.09 vs 0.07) (Supplementary Tables 1 and 2). The effect size comparing the annual percentage change in tau SUVR for the MCI A β + group compared to the CU A β - group was greater for SUVR_{WM} than SUVR_{Cb} in all composite ROI (Me, d = 0.08 vs 0.02; MT, d = 0.18 vs 0.08; Te, d = 0.41 vs 0.34; R, d = 0.38 vs 0.28) (Supplementary Tables 1 and 2). The effect size for annual percentage change in tau SUVR in Te and R was greater for SUVR_{WM} when comparing AD A β + to the CU A β - group (Te, d = 0.23 vs 0.06; R, d = 0.60 vs 0.27) (Supplementary Tables 1 and 2). CU A β - had higher annual

percentage change in tau SUVR than AD A β + in Me and MT, where AD A β + had negative rates of change. The effect size for this difference was greater for SUVR_{WM} than SUVR_{Cb} (Me, d = 0.69 vs 0.38; MT, d = 0.41 vs 0.10).

Change in reference region SUV

The rate of SUV change per year in the cerebellar cortex (Supplementary Figure 2A) and eroded subcortical white matter reference region (Supplementary Figure 2B) was not significantly different when comparing CU A β + and MCI A β + to the CU A β -group. AD A β + had significantly higher rate of SUV change in the cerebellar cortex (p<0.05) and the eroded subcortical white matter reference regions (p<0.001) than the CU A β - group (Supplementary Figure 2). Supplementary Figure 3 shows plots of SUV change by age for the two reference regions. A subset of AD A β + participants under the age of 65 were observed to have an increase in SUV in the eroded subcortical white matter reference region; a finding that was not observed for the cerebellar cortex reference region.

Age, baseline tau and the spatiotemporal trajectory of tau accumulation

The relationship between tau accumulation and age is shown in Figure 5, while the relationship between baseline tau and tau accumulation in composite ROI is shown in Figure 6. The observed spatiotemporal trajectory of tau accumulation (as normalized to the cerebellar cortex) is shown in Figure 7.

Figure 1 Annual rate of ¹⁸F-MK6240 accumulation across the clinical groups (cerebellar cortex reference region)



Vertex-based surface analysis demonstrating the spatial distribution and rate of 18 F-MK6240 accumulation (SUVR/ year) for each clinical group, normalized to the cerebellar cortex. Abbreviations: CU = cognitively unimpaired; CI = cognitively impaired; MCI = mild cognitive impairment; and AD = Alzheimer's disease dementia.

		СU Аβ- (<i>n</i>	= 83)		$\mathbf{CU}\mathbf{A\beta}+(n=37)$				MCI A β + ($n = 19$)			AD $A\beta + (n = 19)$		
ROI	Baseline	Δ SUVR/	Baseline	Т	Δ SUVR/ yr	Т	Baseline	Т	Δ SUVR/ yr	Т	Baseline	Т	Δ SUVR/ yr	Т
	SUVR	yr	SUVR	stat		stat	SUVR	stat		stat	SUVR	stat		stat
Me	0.89±0.16	0.0121±0.	1.16±0.26	5.81	0.0418±0.0836	2.00	1.55±0.62***	4.60	0.0152±0.0922	0.14	1.88±0.76***	5.65	-0.0379±0.1631	-1.32
		0507	***		*									
МТ	0.98±0.15	0.0142±0.	1.24±0.28	5.42	0.0478±0.0833	2.28	1.75±0.78***	4.32	0.0308±0.1022	0.69	2.29±0.95***	6.02	0.0082±0.2144	-0.12
		0479	***		*									
Te	1.02±0.14	0.0093±0.	1.17±0.23	3.73	0.0346±0.0764	1.84	1.63±0.72	3.66	0.0359±0.1000	1.13	2.64±1.39***	5.07	0.0581±0.2678	0.79
		0510	***		*		***							
R	0.88±0.12	0.0018±0.	0.94±0.15	2.46	0.0099±0.0670	0.68	1.23±0.62	2.42	0.0300±0.0930	1.29	1.71±0.96***	3.74	0.0767±0.1851	1.75
		0393	**				*						*	

Table 2 Baseline and annual tau SUVR change (cerebellar cortex reference region)

Baseline tau SUVR and annual tau SUVR change per year (Δ SUVR/ year), normalized to the cerebellar cortex. T stat = t statistic from a one-tailed t-test comparing the A β + clinical groups against the CU A β - group, * p \leq 0.05, **p \leq 0.01, *** p \leq 0.001. Abbreviations: Me = mesial temporal; MT = meta-temporal; Te = temporoparietal; R = rest of neocortex.

	$\mathbf{CU} \mathbf{A\beta} \cdot (n = 83)$			CU A β + ($n = 37$)				MCI A β + ($n = 19$)				AD $A\beta$ + ($n = 19$)			
ROI	Baseline	Δ SUVR/ yr	Baseline	Т	Δ SUVR/ yr	Т	Baseline	Т	Δ SUVR/ yr	Т	Baseline	Т	Δ SUVR/ yr	Т	
	SUVR		SUVR	stat		stat	SUVR	stat		stat	SUVR	stat		stat	
Me	1.18±0.13	0.0233±0.0766	1.51±0.36*	5.41	0.0564±0.0938*	2.04	1.88±0.67*	4.55	0.0245±0.1386	0.04	2.07±0.55**	7.07	-0.0501±0.1141	-2.67	
			**				**				*		**		
MT	1.30±0.13	0.0287±0.0775	1.61±0.37*	5.02	0.0646±0.0839*	2.29	2.10±0.75*	4.61	0.0457±0.1342	0.53	2.51±0.68**	7.78	-0.0014±0.1333	-0.95	
			**				**				*				
Te	1.36±0.16	0.0240±0.0861	1.52±0.31*	2.94	0.0440±0.0769	1.22	1.96±0.66*	3.90	0.0633±0.1049*	1.72	2.83±1.04**	6.15	0.0430±0.1538	0.52	
			*				**				*				
R	1.18±0.16	0.0131±0.0770	1.22±0.21	1.21	0.0112±0.0798	-0.12	1.47±0.55*	2.23	0.0419±0.0623	1.52	1.84±0.66**	4.33	0.0707±0.1416	1.71	
											*				

Baseline tau SUVR and annual tau SUVR change per year (Δ SUVR/ yr), normalized to the eroded subcortical white matter reference region. T stat = t statistic from a one-tailed t-test comparing the A β + clinical groups against the CU A β - group, * p≤0.05, **p≤0.01, *** p≤0.001. Abbreviations: Me = mesial temporal; MT = meta-temporal; Te = temporoparietal; R = rest of neocortex.



Figure 2 Annual rate of tau SUVR change in composite ROI

Boxplots showing annual tau SUVR change in composite ROI for the clinical groups, normalized to A) cerebellar cortex reference region; and B) eroded subcortical white matter reference region. The red dashed vertical line represents zero change. Within the boxes, the line represents the median value. The whiskers extend from the 5th to the 95th percentile. Abbreviations: CU = cognitively unimpaired; MCI =mild cognitive impairment; AD = Alzheimer's disease dementia.



Figure 3 Annual percentage change in tau SUVR in composite ROI

Boxplots showing annual percentage change in tau SUVR in composite ROI for the clinical groups, normalized to A) cerebellar cortex reference region; and B) eroded subcortical white matter reference region. The red dashed vertical line represents zero change. Within the boxes, the line represents the median value. The whiskers extend from the 5th to the 95th percentile. Abbreviations: CU = cognitively unimpaired; MCI = mild cognitive impairment; AD = Alzheimer's disease dementia.



Figure 4 Annual tau SUVR change by region

Annual tau SUVR change across brain regions for the clinical groups, normalized to A) cerebellar cortex reference region; and B) eroded subcortical white matter reference region. The red dashed vertical lines represent zero change. Within the boxes, the line represents the median value. The whiskers extend from the 5th to the 95th percentile. Abbreviations: Me = mesial temporal; MT = meta-temporal; Te = temporoparietal; R = rest of neocortex.



Figure 5 Tau change in composite ROI by age

Tau SUVR in composite ROI by age, normalized to A) cerebellar cortex reference region; and B) eroded subcortical white matter reference region. The vertical black dashed line separates participants above and below 75 years of age. The horizontal black dashed line represents the 95% percentile of CU A β -. Blue = cognitively unimpaired (CU). Orange = MCI. Red = AD dementia. Dash lines represent A β - and solid lines represent A β +. Abbreviations: Me = mesial temporal, MT = meta-temporal, Te= temporoparietal, and R = rest of neocortex.



Figure 6 Relationship between baseline tau and rate of accumulation in composite

Relationship between baseline tau SUVR and rate of change (SUVR/ year) for each composite ROI, normalized to A) cerebellar cortex reference region; and B) eroded subcortical white matter reference region. Blue = cognitively unimpaired; green = MCI; red = Alzheimer's disease dementia; empty circles = $A\beta$ -; solid circles = $A\beta$ +.



Figure 7 Spatiotemporal trajectory of tau accumulation

Figure 7 shows the natural history of regional tau accumulation measured as ¹⁸F-MK6240 SUVR normalized to the cerebellar cortex reference region, as interpolated from the data. Solid horizontal lines represent the mean CU Aβ- SUVR_{Cb} values for the composite ROI (Me: 0.89, Te: 1.02; R: 0.88). Dashed horizontal lines represent the mean AD Aβ+ SUVR_{Cb} values for the composite ROI (Me: 1.88, Te: 2.64, R: 1.71). To reach the mean SUVR_{Cb} observed in AD Aβ+ from the mean SUVR_{Cb} observed in CU Aβ-, it takes approximately 25 years in Me, 21 years in Te, and 19 years in R. Abbreviations: Me = mesial temporal (green), Te= temporoparietal (red), and R = rest of neocortex (blue).

Discussion

Serial tau imaging with ¹⁸F-MK6240 was able to detect tau accumulation in both cognitively unimpaired (CU) and cognitively impaired participants (MCI and AD in equal proportion) who were $A\beta$ + at baseline. Tau accumulation rates were evaluated independently using composite ROI and vertex-based surface analyses, with concordant results for these groups. Accumulation of tau was predominantly observed in mesial temporal and temporoparietal regions in CU $A\beta$ +, in temporoparietal regions in MCI $A\beta$ +, and in frontal regions in AD $A\beta$ +. ROI and vertex-based analyses showed low rates of tau SUVR_{Cb} accumulation in CU $A\beta$ -, confined to mesial and meta-temporal regions, while low rates of tau SUVR_{WM} accumulation were also observed to involve temporoparietal regions.

Annual rates of tau SUVR_{WM} accumulation were higher for CU A β -, CU A β +, and MCI A β + groups compared to SUVR_{Cb}, with fewer observed outliers. However, tau SUVR_{Cb} accumulation rates were higher for AD A β +. A subset of young (<65 years of age) AD A β + individuals were observed to have a SUV increase in the eroded subcortical white matter reference region, due to either tau accumulation or spill-over of the ¹⁸F-MK6240 signal into the eroded subcortical white matter mask for this reference region, which lowered the estimated SUVR_{WM} and the yearly rate of change for these individuals.

As observed with $A\beta$, the regional rates of tau accumulation were dependent on baseline tau burden. AD $A\beta$ + with very high levels of baseline tau (SUVR>3) showed either a plateau or decline in tau SUVR. This was most apparent in mesial temporal and temporoparietal regions. Plots of regional tau SUVR and age showed that participants with high baseline tau (SUVR>3) were young (<75 years of age) and cognitively impaired (AD $A\beta$ + > MCI $A\beta$ +). This study also estimated the spatiotemporal trajectory of tau accumulation. While tau starts accumulating early in Me (reaching the threshold for abnormality ~6.6 and ~7.5 years earlier than in Te and R, respectively), it slows down in the Me as the disease progresses. It takes

about 25 years to get from the levels of CU A β - SUVR to the SUVR observed in AD patients, and about 18 years after crossing the threshold of abnormality. Conversely, tau accumulation in Te accelerates, starting to insinuate a plateau at very high tau levels, while tau starts accumulating later in the R composite region with less tendency to plateau at very high levels. In Te, it takes about 21 years to get from the levels of CU A β - SUVR to the SUVR observed in AD patients, and about 15 years after crossing the threshold of abnormality. In R, where tau starts accumulating much later, it takes about 19 years to get from the levels of A β -CU SUVR to the SUVR observed in AD patients, and about 15 years after crossing the threshold of as after crossing the threshold of abnormality.

Minimal tau accumulation in CU A β - is consistent with prior longitudinal analyses (13, 19, 21-23), and consistent with observations that tau accumulation is accelerated in the context of A β (8, 19, 24). The low rates of tau accumulation in CU A β - confined to mesial temporal and temporal regions may be consistent with primary age-related tauopathy (PART) (25). A β + younger individuals (<65 years) have been observed to have a higher baseline cortical tau burden (21, 26), and more rapid accumulation in longitudinal tau ¹⁸F-flortaucipir PET analyses (21, 26). Few participants in this study were under 65 years of age (7/38 A β + cognitively impaired participants), which may have impacted the group-level rate of tau accumulation.

Based on the results in this study, there are a few points of relevance to AD clinical trials that opt to use tau ¹⁸F-MK6240 as an outcome measure. Selection of composite ROI for use in a therapy trial should take into consideration that a meta-temporal composite may be ideal for early detection and useful in the assessment of tau accumulation at the preclinical disease stages, while a neocortical composite focusing on temporoparietal regions may be more sensitive to detect changes at the symptomatic stages of disease. The observation of a plateau or decline in the rate of tau accumulation in AD A β + participants with very high levels of

baseline tau should be kept in mind when interpreting results of disease-modifying therapies that are aiming to demonstrate clearance or slowing of tau accumulation. Reference region selection is also another important consideration. While both the cerebellar cortex and an eroded subcortical white matter reference region may be suitable to be used for clinical trials targeting preclinical AD, the cerebellar cortex reference region would be preferred for trials in symptomatic AD (particularly for a cohort recruiting younger participants).

Limitations

There were a few important limitations to this study. The sample size was relatively small, particularly with low numbers in the $A\beta$ + cognitively impaired groups. Participants in this study had high levels of education and did not have significant medical or psychiatric comorbidities. AD $A\beta$ + participants had mild dementia (MMSE 22.2±3.5). While these features may be consistent with characteristics of participants recruited to clinical trials, individuals with more severe disease and medical comorbidities, were not represented in this sample and thus may not be widely generalizable. Additionally, the duration of follow-up in this study was shorter than would typically be expected for a preclinical AD trial. This study was also limited by the lack of a replication cohort to validate these findings.

Conclusion

Longitudinal tau ¹⁸F-MK6240 PET detected tau accumulation in both preclinical and symptomatic Alzheimer's disease with 12-24 months follow-up. The regional rate of tau accumulation was influenced by baseline tau burden. Interpolation of the data suggests that tau accumulation takes approximately two decades to reach the levels observed in AD. The use of tau ¹⁸F-MK6240 PET as an outcome measure for clinical trials should take into consideration the selection of composite ROI, regional baseline tau burden, and choice of reference region, depending on whether the trial is targeting preclinical or symptomatic disease stages.

Declarations

Ethics approval and consent

This study was approved by the Austin Health Human Research Ethics Committee and written informed consent was obtained from all participants.

Consent for publication

All participants gave written consent for publication of de-identified data.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

CCR was the recipient of a research grant from Cerveau, who supplied the MK6240 tau tracer precursor for research use. CCR has received grants from Cerveau Technologies (institution), Eisai (institution) and Biogen (institution). CCR has received consulting fees from Nutricia (speaker fee), Prothena and Biogen (for preparation of educational material). CCR has participated on a data safety board/ advisory board for Cerveau Technologies (unpaid). VLV has received consulting fees from IXICO, Eli Lilly, Life molecular imaging and Hospicom and has received payment/ honoraria from ACE Barcelona. NK, VD, PB, JR, LW, CF, JF and CLM do not report any disclosures.

Funding

This work was supported by the National Health and Medical Research Council (NHMRC) (grant numbers APP1132604, APP1140853). NK was supported by a cofunded PhD scholarship from Australian Rotary Health/ Estate of Bartolina Peluso.

Author contributions

CCR and VLV contributed to study conception and design. VLV also contributed to generation of the figures highlighting the relationship between baseline tau and accumulation, and the natural history of tau accumulation. NK contributed to statistical and image analysis, generation of figures, interpretation of results, and wrote the manuscript. VD contributed to data processing, analysis, vertex-based surface analysis, and interpretation of results. PB contributed to data processing, analysis, and interpretation of results. All authors critically reviewed the manuscript for intellectual content.

Acknowledgements

The data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of aging (AIBL), funded by the Commonwealth Scientific and Industrial Research Organization (CSIRO), National Health and Medical Research Council (NHMRC), and participating institutions. AIBL researchers are listed at www.aibl.csiro.au. The authors thank all participants who took part in this study, as well as their families.

Abbreviations

CU: cognitively unimpaired

Me: mesial temporal composite

MT: meta-temporal composite

Te: temporoparietal composite

R: rest of neocortex composite

SUVR: standardized uptake value ratio

 $SUVR_{Cb}$: standardized uptake value ratio normalized to a cerebellar cortex reference region $SUVR_{WM}$: standardized uptake value ratio normalized to an eroded subcortical white matter reference region

MTL: mesial temporal lobe

AIBL: Australian Imaging Biomarkers and Lifestyle Study of Ageing

References

1. Devous MD, Sr., Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, et al. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. J Alzheimers Dis. 2021;80(3):1091-104.

 Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551-67.

3. Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017;140(12):3286-300.

4. Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol. 2017;74(4):427-36.

5. Mattsson N, Insel PS, Donohue M, Jogi J, Ossenkoppele R, Olsson T, et al. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer's disease. Alzheimers Dement. 2019;15(4):570-80.

6. Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, et al. Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. Alzheimers Res Ther. 2019;11(1):60.

7. Gordon BA, McCullough A, Mishra S, Blazey TM, Su Y, Christensen J, et al. Crosssectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. Alzheimers Dement (Amst). 2018;10:245-52.

8. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019;76(8):915-24.

26

9. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021;384(18):1691-704.

10. Budd-Haeberlein S, Von Hein C, Tian Y, Chalkias S, Muralidharan K, editors. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer's disease. Clinical Trials on Alzheimer's Disease Conference; 2019.

11. Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles. J Nucl Med. 2016;57(10):1599-606.

12. Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.

Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M,
et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain.
2021.

14. Aisen PS, Zhou J, Irizarry MC, Kramer LD, Swanson CJ, Dhadda S, et al. AHEAD 3-45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimer's & Dementia. 2020;16(S9).

15. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):672-87.

16. Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, et al. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and

27

Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. J Alzheimers Dis Rep. 2021;5(1):443-68.

17. Dore V, Bourgeat P, Burnham SC, Martins RN, Masters CL, Ames D, et al. Automated reporting of tau PET quantification on the brain surface. Alzheimer's & Dementia. 2019;15:P1269-P.

Villemagne V, Dore V, Bourgeat P. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. J Mol Med Ther 2017; 1 (1):
25-32 26 J Mol Med Ther 2017 Volume 1 Issue. 2017;1:3.

19. Jack CR, Jr., Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer's disease. Brain. 2018;141(5):1517-28.

20. Bourgeat P, Dore V, Fripp J, Ames D, Masters CL, Salvado O, et al. Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage. 2018;183:387-93.

21. Smith R, Strandberg O, Mattsson-Carlgren N, Leuzy A, Palmqvist S, Pontecorvo MJ, et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain. 2020;143(12):3805-15.

22. Cho H, Choi JY, Lee HS, Lee JH, Ryu YH, Lee MS, et al. Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. J Nucl Med. 2019;60(11):1611-21.

23. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain. 2019;142(6):1723-35.

24. Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Predicting future rates of tau accumulation on PET. Brain. 2020;143(10):3136-50.

28

25. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-66.

26. Sintini I, Martin PR, Graff-Radford J, Senjem ML, Schwarz CG, Machulda MM, et al. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. Neuroimage Clin. 2019;23:101823.